Mihad has a wealth of product experience. He has spent the last 10 years leading the development of data-driven products for the clinical trials sector. Working with leading academic and commercial research organisations, he managed the development of a suite of data-driven products on the EMIS-X Analytics platform.

Jenny is the Product Owner for Pathway, overseeing the quality and usability of the product. She determines what features are developed and when they are released.

Dr Ian Wood is an active NHS GP and a Clinical Director at EMIS

As a clinician with a background in both General Practice, digital therapeutics and mental health, Ian has a unique experience in how technology can be used to enhance and enable person-centred care.

He has led the implementation of groundbreaking treatments across the NHS and is driven by a passion for using technology to transform traditional care pathways to not only benefit patients but also to empower clinicians and improve the overall efficiency of the NHS.

As the Director of Partners and Life Sciences at EMIS, Jamie leads a team of professionals who are passionate about transforming healthcare through data and technology. He develops and manages partnerships with life sciences companies, research institutions, and government agencies, leveraging EMIS’s data platform and solutions.

Simon currently leads the inward investment team at SDI which focuses on Offshore Wind, Hydrogen and Green Heat Projects. With over 15 years’ of experience in offshore wind projects and a desire to maximise Scottish manufacturing in the global offshore wind supply, Simon is keen to speak about your potential projects in Scotland. Before offshore wind, Simon led the Scottish Enterprise’s Large Company Research and Development Grant team, and has experience in international trade and electronics.

Jonathan is a seasoned leader with a proven track record in driving sales, product growth and market strategy across diverse sectors within the Clinical trials space, including Medical Devices, Biostatistics, and Contract Research Organizations (CROs). As Senior Manager, Product Growth and Market Strategy at 4G Clinical, he leverages his extensive background in sales and operations to identify and capitalize on market opportunities within the Randomization and Trial Supply Management (RTSM) space. Jonathan’s strategic vision and data-driven approach are instrumental in accelerating product adoption and expanding market share, ultimately contributing to the advancement of clinical research and the development of innovative medical solutions.

Gemma Lofts is an accomplished Clinical Supply Chain professional with over 12 years of experience working in oncology, respiratory, cell and gene and controlled drugs. Gemma is currently the Director of Clinical Supply Chain at Bicycle Therapeutics, where she has set up end-to-end processes to support the expansion of their oncology platform from phase 1 into global phase 2/3 registrational trials. As a small biotech moving to mid-size with a fully outsourced model, this included the selection and set up of new vendors and procedures to ensure best practice and compliance.

Benoit Cuyvers is the Upstream AI (Artificial Intelligence) Product Manager for Clario, recently joining the team from the ArtiQ acquisition. (Leuven, Belgium). The acquisition advances our respiratory solutions portfolio, combining Clario’s deep scientific expertise with ArtiQ’s innovative artificial intelligence capabilities. Benoit led the efforts on the ArtiQ AI-enabled Risk Based Monitoring system, from concept to solution and will continue these endeavors in his role at Clario. With his background in Bioscience Engineering and his past experience as a digital health expert at Siemens, Benoit is able to apply learnings from other medical and technical fields to the field of AI in respiratory research & medicine.

Martin is a prominent leader in hospitality technology with extensive expertise across strategy, operations, digital solutions, business partnerships, program management, infrastructure, cybersecurity, and application development.

His career highlights include technology roles at InterContinental, Four Seasons, Radisson, and most recently Marriott International where he spent the last 26 years leading the discipline for Asia Pacific including oversight of the successful integration of Starwood Hotels & Resorts and The Ritz-Carlton.

Recently, he founded Bookallil Advisory, a consulting firm based in Hong Kong, offering technology advisory services to the hospitality sector.

Matthew Albert is Head of Translational Sciences and Early Clinical Development at Octant Biosciences, using cellular intelligence and high throughput approaches to develop corrector therapeutics. Prior roles include: Chief Translational Officer at Human Immunology Biosciences (HI-Bio 2018-2019); and Sr Vice President of Biology and Translational Genetics at insitro, a biotechnology company committed to leveraging biomolecular data at scale for purposes of drug development (2019-2021). He was a Principal Scientist at Genentech, working in the Department of Cancer Immunology where he led a team of immunologists, geneticists, microbiome scientists and mathematicians with the aim to derive new insight from human subject studies and real world data (2015-2019). His prior academic career included INSERM director of research and full professor working at Institut Pasteur, where he headed the Director of the Department of Immunology (2010 – 2015); and was the Founding Director of The Center for Human Immunology at Institut Pasteur (2007 – 2015).

Matthew received his M.D. at Cornell University Medical College and his Ph.D. in Immunology at The Rockefeller University. He trained in Clinical Pathology at The New York Presbyterian Hospital and was a Clinical Scholar at The Rockefeller University Hospital. His basic science and clinical research achievements include the characterization of the cellular and molecular mechanisms underlying the cross-priming of tumor and viral-specific cytolytic T lymphocytes (CTLs). He has also made impactful contributions in the fields of tumor immunity in patients with bladder cancer; and helped to define the complex role of type I IFNs in HCV disease pathogenesis.

He has successfully launched a commercialized biomarker assay for agonist and antagonist forms of CXC10, in partnership with Myriad-RBM; and established point-of-care tests for managing patients with Hepatitis C with Epistem, Inc. Other notable achievements include coordination of multiple international projects, including the The Milieu Intérieur Project: Defining the genetic and environmental determinants of immune phenotype variance – establishing a path towards personalized medicine.